Published in J Transl Med on November 30, 2009
Immune monitoring using the predictive power of immune profiles. J Immunother Cancer (2013) 1.36
Cytokines in radiobiological responses: a review. Radiat Res (2012) 1.29
High-sensitivity C-reactive protein and cancer. J Epidemiol (2011) 1.17
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther (2010) 1.06
The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses. Cancer Manag Res (2012) 1.02
Persistent elevation of C-reactive protein following esophagogastric cancer resection as a predictor of postoperative surgical site infectious complications. World J Surg (2011) 0.99
Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma. Mayo Clin Proc (2014) 0.89
Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Manag Res (2012) 0.88
Modeling putative therapeutic implications of exosome exchange between tumor and immune cells. Proc Natl Acad Sci U S A (2014) 0.87
In silico tumor control induced via alternating immunostimulating and immunosuppressive phases. Virulence (2015) 0.84
Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biol Ther (2015) 0.82
Cancer therapeutic potential of combinatorial immuno- and vasomodulatory interventions. J R Soc Interface (2015) 0.79
Dendritic cell therapy for oncology roundtable conference. J Immune Based Ther Vaccines (2011) 0.78
Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates. F1000Res (2015) 0.77
Mulberry leaf reduces oxidation and C-reactive protein level in patients with mild dyslipidemia. Biomed Res Int (2013) 0.77
C-reactive Protein and Disease Outcome in Nigerian Sickle Cell Disease Patients. Ann Med Health Sci Res (2014) 0.75
Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma. J Immunother Cancer (2014) 0.75
Preclinical evaluation of a TEX101 protein ELISA test for the differential diagnosis of male infertility. BMC Med (2017) 0.75
Roles of preoperative C-reactive protein are more relevant in buccal cancer than other subsites. World J Surg Oncol (2017) 0.75
Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations. J Transl Med (2014) 0.75
Personalized therapy for metastatic melanoma: could timing be everything? Future Oncol (2012) 0.75
Oxidative stress and insulin resistance in policemen working shifts. Int Arch Occup Environ Health (2015) 0.75
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 15.85
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
C-reactive protein: a critical update. J Clin Invest (2003) 11.77
SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS. J Exp Med (1930) 10.97
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell (2004) 5.59
C-reactive protein and the risk of incident colorectal cancer. JAMA (2004) 4.94
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med (2005) 3.22
Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol (2005) 3.15
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control (2008) 2.68
Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol (2009) 2.61
The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep (2002) 2.47
Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med (2006) 2.32
Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem (2001) 2.01
Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes (2007) 1.86
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res (2008) 1.60
Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation (2007) 1.47
Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol (2006) 1.46
Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med (2008) 1.31
Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother (2008) 1.18
C-reactive protein: structural biology, gene expression, and host defense function. Immunol Res (1997) 1.18
C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol (2007) 1.17
Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest (2009) 1.17
Cytokine-driven cell cycling is mediated through Cdc25A. J Cell Biol (2005) 1.15
Cytokine signals in T-cell homeostasis. J Immunother (2005) 1.07
Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer (2004) 1.02
Absolute quantification of C-reactive protein in human plasma derived from patients with epithelial ovarian cancer utilizing protein cleavage isotope dilution mass spectrometry. J Proteome Res (2009) 0.99
Elevation of C-reactive protein level is associated with synchronous and advanced colorectal neoplasm in men. Am J Gastroenterol (2008) 0.98
Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie (2008) 0.96
Induction of glycosylation in human C-reactive protein under different pathological conditions. Biochem J (2003) 0.92
Cyclic haemopoiesis at 7- or 8-day intervals. Br J Haematol (1994) 0.79
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci U S A (2008) 2.70
Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc Natl Acad Sci U S A (2005) 2.26
In-transit melanoma: an individualized approach. Oncology (Williston Park) (2011) 2.24
An alternative cost effectiveness analysis of ThinPrep in the Australian setting. Aust N Z J Obstet Gynaecol (2005) 2.04
Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol (2007) 1.97
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood (2009) 1.74
The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma (2012) 1.72
Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol (2007) 1.66
Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer (2007) 1.63
Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem (2011) 1.60
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica (2011) 1.60
Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol (2006) 1.59
Therapy for metastatic melanoma: the past, present, and future. BMC Med (2012) 1.57
Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Vaccine (2008) 1.48
Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count. Am J Hematol (2010) 1.46
Clearance of human papillomavirus in women treated for cervical dysplasia. Obstet Gynecol (2011) 1.45
Ovarian cancer: patterns of care in Victoria during 1993-1995. Med J Aust (2002) 1.42
Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant (2008) 1.37
Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol (2006) 1.36
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood (2002) 1.34
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol (2008) 1.33
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc (2010) 1.32
Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One (2012) 1.31
Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol Cancer (2013) 1.27
Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer (2006) 1.27
Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc (2009) 1.25
Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog (2007) 1.25
Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res (2009) 1.25
Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol (2011) 1.24
Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. J Pathol (2003) 1.24
A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Cancer (2010) 1.22
On the validation of models of forest CO2 exchange using eddy covariance data: some perils and pitfalls. Tree Physiol (2005) 1.21
Vemurafenib for melanoma metastases to the brain. N Engl J Med (2011) 1.21
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther (2012) 1.20
HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. J Med Virol (2009) 1.18
Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol (2008) 1.17
Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol (2002) 1.16
Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics (2005) 1.15
Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. J Histochem Cytochem (2002) 1.15
Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol (2009) 1.14
Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. Leuk Lymphoma (2012) 1.14
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res (2012) 1.13
Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc (2008) 1.13
Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer (2002) 1.09
Timed ablation of regulatory CD4+ T cells can prevent murine AIDS progression. J Immunol (2004) 1.06
Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc (2002) 1.05
Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol (2010) 1.05
Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma. J Am Acad Dermatol (2004) 1.03
Removal of blood components from cervical smears: implications for cancer diagnosis using FTIR spectroscopy. Biopolymers (2003) 1.03
The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses. Cancer Manag Res (2012) 1.02
Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys (2013) 1.02
Height-growth response to climatic changes differs among populations of Douglas-fir: a novel analysis of historic data. Ecol Appl (2012) 1.01
Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc (2012) 1.00
Clopidogrel-associated autoimmune thrombocytopenic purpura. Catheter Cardiovasc Interv (2004) 1.00
Chylothorax in chronic lymphocytic leukemia patient. Am J Hematol (2002) 1.00
Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol (2007) 0.98
Percutaneous cryoablation of musculoskeletal oligometastatic disease for complete remission. J Vasc Interv Radiol (2012) 0.97
Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc (2004) 0.97
Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology (2013) 0.97
Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Mod Pathol (2010) 0.97
Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens. Cancer Res (2010) 0.97
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol (2012) 0.97
Detection of endometrial cancer by determination of matrix metalloproteinases in the uterine cavity. Gynecol Oncol (2003) 0.96
Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas. Cancer (2007) 0.96
Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study. Am J Clin Oncol (2014) 0.95
Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am J Clin Oncol (2003) 0.95
Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc (2011) 0.95
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer (2010) 0.95
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood (2011) 0.95
The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res (2016) 0.94
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res (2005) 0.94
A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer (2007) 0.94
Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma. Clin Cancer Res (2004) 0.93
Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma (2014) 0.93
Effects of a simple plant morphological mutation on the arthropod community and the impacts of predators on a principal insect herbivore. Oecologia (2003) 0.92
Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol (2014) 0.92
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer (2014) 0.91
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol (2014) 0.91
Treatment of brain metastases from melanoma. Mayo Clin Proc (2003) 0.90
Endometrial cancer. Best Pract Res Clin Obstet Gynaecol (2012) 0.90
Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. Gynecol Oncol (2004) 0.89
Treatment of microinvasive adenocarcinoma of the uterine cervix: a retrospective study and review of the literature. Gynecol Oncol (2007) 0.89
Organizing pneumonia in patients with hematologic malignancies: a steroid-responsive lesion. Respir Med (2006) 0.88
Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Manag Res (2012) 0.88
Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma (2003) 0.88
Differential response of human and mouse dendritic cells to VEGF determines interspecies discrepancies in tumor-mediated TH1/TH2 polarity shift. Clin Cancer Res (2011) 0.88
Hormonal therapies and gynaecological cancers. Best Pract Res Clin Obstet Gynaecol (2007) 0.86
Fluctuation of systemic immunity in melanoma and implications for timing of therapy. Front Biosci (Elite Ed) (2012) 0.86
Regional lymphatic immunity in melanoma. Melanoma Res (2012) 0.86
Novel therapeutics for the treatment of metastatic melanoma. Future Oncol (2009) 0.86
A three-dimensional multivariate image processing technique for the analysis of FTIR spectroscopic images of multiple tissue sections. BMC Med Imaging (2006) 0.86
Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Melanoma Res (2011) 0.86
Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma. Clin Dev Immunol (2011) 0.86
Pediatric melanoma: analysis of an international registry. Cancer (2013) 0.86